These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
218 related items for PubMed ID: 29926994
1. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs. Marsella R, Ahrens K. Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994 [Abstract] [Full Text] [Related]
3. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303 [Abstract] [Full Text] [Related]
4. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR. Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322 [Abstract] [Full Text] [Related]
5. Lack of Interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs. Aleo MM, Messamore J, Nieto BA, Fleck TJ, Humphrey WR, Coscarelli EM, Mahabir SP, McCall RB, Gonzales AJ. Vet Immunol Immunopathol; 2023 Feb; 256():110537. PubMed ID: 36603446 [Abstract] [Full Text] [Related]
16. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. Carrasco I, Ferrer L, Puigdemont A. J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749 [Abstract] [Full Text] [Related]
17. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis. Nishiyama T, Kusakabe M, Imanishi I, Hisano T, Fukamachi T, Taguchi N, Iyori K, Hsiao YH. Vet Dermatol; 2023 Dec; 34(6):523-531. PubMed ID: 37485602 [Abstract] [Full Text] [Related]
18. Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial. Takahashi J, Kanda S, Imanishi I, Hisano T, Fukamachi T, Taguchi N, Momiyama S, Nishiyama S, Motegi T, Iyori K. Vet Dermatol; 2021 Apr; 32(2):119-e25. PubMed ID: 33185330 [Abstract] [Full Text] [Related]
19. Is the skin barrier abnormal in dogs with atopic dermatitis? Olivry T. Vet Immunol Immunopathol; 2011 Nov 15; 144(1-2):11-6. PubMed ID: 21835476 [Abstract] [Full Text] [Related]
20. The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study. Rynhoud H, Croton C, Henry G, Meler E, Gibson JS, Soares Magalhaes RJ. BMC Vet Res; 2022 Apr 27; 18(1):151. PubMed ID: 35477466 [Abstract] [Full Text] [Related] Page: [Next] [New Search]